Combining Isocitrate Dehydrogenase Inhibitors With Existing ...

Identification of recurrent mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) in patients with acute myeloid leukemia (AML) coupled with an ...

Combining Isocitrate Dehydrogenase Inhibitors With Existing

We review current treatment strategies incorporating IDHi and discuss future challenges and opportunities in the treatment of IDH-mutated AML.

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape. Lachowiez C 1 ,. DiNardo CD ...

Combining Isocitrate Dehydrogenase Inhibitors With Existing ...

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia · Curtis A. Lachowiez, C. Dinardo, Etyan Stein · Published in ...

Combination treatment of an IDH1 inhibitor with chemotherapy in ...

Add to an existing collection. Name your collection: Name must ... mutant isocitrate dehydrogenase 1. CR, complete remission. CRi, CR with ...

Combining Isocitrate Dehydrogenase Inhibitors With Existing ... - OUCI

Abstract Identification of recurrent mutations in isocitrate dehydrogenase genes ( IDH1 and IDH2) in patients with acute myeloid leukemia (AML) coupled with ...

Management of isocitrate dehydrogenase 1/2 mutated acute ...

Ivosidenib (AG-120), is a highly selective, reversible, small molecule inhibitor of mutant IDH1 and was the first Food and Drug Administration ( ...

Clinical Implications of Isocitrate Dehydrogenase Mutations ... - MDPI

Combining Isocitrate Dehydrogenase Inhibitors with Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape. Cancer J. 2022, 28, 21–28 ...

Isocitrate Dehydrogenase Inhibitor - an overview - ScienceDirect.com

Isocitrate dehydrogenases (IDH) are essential metabolic enzymes in the tricarboxylic acid (TCA) cycle involved with catalyzing the conversion of isocitrate to ...

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) — and azacitidine showed encouraging clinical ...

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer ...

AGI-6780 is a urea sulfonamide inhibitor of the IDH2R140Q mutant enzyme specifically and exhibits non-competitive inhibition with respect to substrate, and ...

Acute myeloid leukemia with IDH1 and IDH2 mutations - Nature

DiNardo, C. D. et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid ...

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid ...

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia ( ...

The regulatory mechanisms and inhibitors of isocitrate ...

IDH1-IN-6 is a potent, selective, and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50 of 6.27 and 3.71 nmol/L for IDH1R132H and IDH1 ...

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or ...

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a ...

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

AML = acute myeloid leukemia; IDH = isocitrate dehydrogenase. IDH inhibitors as monotherapy. The IDH1 inhibitor ivosidenib and the IDH2 inhibitor enasidenib ...

Isoform Switching as a Mechanism of Acquired Resistance to Mutant ...

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition ... combined inhibition of both IDH isoforms (Fig. 4B) ...

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute ...

Ivosidenib or enasidenib combined with intensive chemotherapy in ...

Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, ...